Medicare's GLP-1 bridge program launches July 1 with a $50 monthly copay after major insurers rejected the original BALANCE coverage plan for weight-loss drugs like Wegovy and Zepbound. Donald Trump Bible reading: Full text and what passage means Iran says ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers. The Centers for Medicare & Medicaid Services first announced the Better Approaches to Lifestyle and Nutrition for ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.

The federal government scrapped a plan to have health insurance companies fund coverage of obesity drugs for seniors, opting instead to pay for the medicine with taxpayer dollars through the

Adults who use a GLP-1 have lower macronutrient intake than nonusers, according to data that will be presented at the European Congress on Obesity. In an analysis of data from adults with overweight or obesity using a health app,

About 12% of Americans have used GLP-1 drugs like Ozempic or Wegovy. The eating patterns those medications are driving — smaller portions, more protein, bold global flavors, less ultra-processed food — happen to be solid nutritional principles for anyone.

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that “2025 was probably the single most exciting year in my entire journey.

Here are five key things investors need to know to start the trading day.